Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2003

View Archived Issues

Argenta identifies candidate series in Pharmagene IBS collaboration

Glucocorticoid receptor antagonists as a potential alternative therapy for depression

NIAID grant supports development of RNAi approach for hepatitis B treatment

Large Scale Biology awarded HIV vaccine research grant

Positive phase IIIb results for MT-100

Potential use of MCH1 receptor antagonists in anxiety and depression

New data on ST-1535, a novel selective adenosine A2A receptor antagonist

Nemifitide well tolerated in patients with major depression

No discontinuation symptoms following treatment with agomelatine for major depression

Evidence of clinical benefits for COX-2 inhibitors in schizophrenia

Divalproex more effective than gabapentin against aggressive behavior

Reduced risk of relapse with duloxetine in major depression

Ariad scientists design new rapamycin-based immunosuppressants

Yamanouchi claims new BK(Ca) channel openers for use in urinary incontinence

Novel gamma-secretase inhibitors prepared and tested by Schering and Pharmacopeia scientists

Patient dosing begins in phase III satraplatin trial for prostate cancer

Galileo patent covers novel agents for oxidative stress-related disorders

DNA-binding free radical scavengers with potential as chemoprotective agents

Dual Tie-2/VEGFR2 inhibitors claimed by GSK researchers

Aventis enters SARS vaccine development agreement with NIAID

Orphan drug status granted for Voraxaze

FDA requests additional data on lumiracoxib

New phase III trial evaluates Humira for Crohn's disease

Approvable letter issued for Lexapro in GAD

Genentech completes Avastin BLA filing

ZymoGenetics and Serono initiate phase I trial with TACI-Ig

Telomerase-targeting vaccines in development at GemVax

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...